Structure Therapeutics
Open
$43.01
Prev. Close
$43.04
High
$43.18
Low
$42.90
Market Snapshot
$3.04B
-17.8
-0.86
220
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company is headquartered in South San Francisco, California and currently employs 220 full-time employees. The company went IPO on 2023-02-03. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. The company is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. The company is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
Structure Therapeutics announced positive results from its Phase 2b trial, enhancing its prospects in developing innovative therapies for various diseases.
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company is headquartered in South San Francisco, California and currently employs 220 full-time employees. The company went IPO on 2023-02-03. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. The company is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. The company is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
Recently from Cashu
Structure Therapeutics at AACR 2025: Promising Innovations in Cancer Therapies
Innovative Advances in Cancer Therapy: Domain Therapeutics Prepares for AACR 2025 Domain Therapeutics is poised to make significant contributions to the oncology landscape at the upcoming American Ass…
Exicure Acquires GPCR Therapeutics to Enhance Hematology Focus and Innovation
Exicure Expands Capabilities with Strategic Acquisition of GPCR Therapeutics Exicure, Inc. significantly bolsters its position in the biopharmaceutical sector through a strategic acquisition of GPCR T…
Exicure Acquires GPCR USA to Enhance R&D and Boost Therapeutic Innovations
Exicure Expands Research Horizons through Strategic Acquisition of GPCR USA Exicure, Inc. is poised to enhance its research capabilities and expand its portfolio following a significant Memorandum of…
Exicure Expands Drug Development through Acquisition of GPCR USA for Enhanced Therapeutics
Exicure Expands Horizons with Acquisition of GPCR USA Exicure, Inc. is poised to enhance its capabilities in drug development through a strategic acquisition of GPCR USA, a subsidiary of GPCR Therapeu…